Sabesp ADR

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.» Mehr auf zacks.com

The study is one of five clinical efforts - three IIT proof-of-concept studies and two Phase 2 studies - of crofelemer for the rare disease indications of SBS-IF and/or microvillus inclusion disease (MVID), an ultrarare congenital diarrheal disorder, in the US, EU, and/or Middle East/North Africa (MENA) regions; availability of IIT proof-of-concept results potentially in Q2 2025 Crofelemer, Jaguar's novel plant-based prescription drug, has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both SBS-IF and MVID SAN FRANCISCO, CA / ACCESSWIRE / December 6, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced that an independent IIT in the U.S. to evaluate the efficacy and safety of crofelemer, Jaguar's novel plant-based anti-diarrheal prescription drug, for the rare disease indication of short bowel syndrome with intestinal failure (SBS-IF) in adults has begun. An overview of the study can be viewed on the ClinicalTrials.gov website.» Mehr auf accesswire.com

Recommend holding Sabesp shares post-3Q24 results due to good trends, but valuation lacks safety margin amid Brazilian economic instability. Net revenues rose 9.6% y/y to $987 million, driven by tariff adjustments and privatization impacts on corporate accounting. Operating costs fell 3.1% y/y, with a strong EBITDA margin of 59.9%, and net income increased 43.7% y/y to $201 million.» Mehr auf seekingalpha.com